Literature DB >> 23590895

Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis.

A Riecher-Rössler1, J K Rybakowski, M O Pflueger, R Beyrau, R S Kahn, P Malik, W W Fleischhacker.   

Abstract

BACKGROUND: Hyperprolactinemia is frequent in patients with schizophrenic psychoses. It is usually regarded as an adverse effect of antipsychotics but has recently also been shown in patients without antipsychotic medication. Our objective was to test whether hyperprolactinemia occurs in antipsychotic-naive first-episode patients (FEPs).
METHOD: In the framework of the European First Episode Schizophrenia Trial (EUFEST), 249 out of 498 FEPs were eligible for this study, of whom 74 were antipsychotic naive. All patients were investigated regarding their serum prolactin levels with immunoassays standardized against the 3rd International Reference Standard 84/500.
RESULTS: Twenty-nine (39%) of the 74 antipsychotic-naive patients showed hyperprolactinemia not explained by any other reason, 11 (50%) of 22 women and 18 (35%) of 52 men.
CONCLUSIONS: Hyperprolactinemia may be present in patients with schizophrenic psychoses independent of antipsychotic medication. It might be stress induced. As enhanced prolactin can increase dopamine release through a feedback mechanism, this could contribute to explaining how stress can trigger the outbreak of psychosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23590895     DOI: 10.1017/S0033291713000226

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  16 in total

Review 1.  Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin.

Authors:  Meritxell Tost; José Antonio Monreal; Antonio Armario; Juan David Barbero; Jesús Cobo; Clemente García-Rizo; Miquel Bioque; Judith Usall; Elena Huerta-Ramos; Virginia Soria; Javier Labad
Journal:  Clin Drug Investig       Date:  2020-01       Impact factor: 2.859

2.  Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study.

Authors:  Srihari Gopal; Rosanne Lane; Isaac Nuamah; Margaret Copenhaver; Jaskaran Singh; David Hough; Mark Bach; Adam Savitz
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

Review 3.  Pseudocyesis, delusional pregnancy, and psychosis: The birth of a delusion.

Authors:  Mary V Seeman
Journal:  World J Clin Cases       Date:  2014-08-16       Impact factor: 1.337

4.  Sex-Specific Associations of Androgen Receptor CAG Trinucleotide Repeat Length and of Raloxifene Treatment with Testosterone Levels and Perceived Stress in Schizophrenia.

Authors:  Samantha J Owens; Thomas W Weickert; Tertia D Purves-Tyson; Ellen Ji; Christopher White; Cherrie Galletly; Dennis Liu; Maryanne O'Donnell; Cynthia Shannon Weickert
Journal:  Mol Neuropsychiatry       Date:  2018-11-20

5.  PROLACTIN LEVEL IN PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA TREATED FOR ONE YEAR WITH ATYPICAL ANTIPSYCHOTICS.

Authors:  V P Matei; T Purnichi; A Mihailescu; R Grigoras
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Oct-Dec       Impact factor: 0.877

Review 6.  The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Authors:  J Peuskens; L Pani; J Detraux; M De Hert
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

7.  Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents.

Authors:  Lucia Margari; Emilia Matera; Maria G Petruzzelli; Marta Simone; Anna L Lamanna; Adriana Pastore; Vincenzo O Palmieri; Francesco Margari
Journal:  Int Clin Psychopharmacol       Date:  2015-03       Impact factor: 1.659

8.  Lack of tolerable treatment options for patients with schizophrenia.

Authors:  Leslie Citrome; Anna Eramo; Clement Francois; Ruth Duffy; Susan N Legacy; Steve J Offord; Holly B Krasa; Stephen S Johnston; Alice Guiraud-Diawara; Siddhesh A Kamat; Patricia Rohman
Journal:  Neuropsychiatr Dis Treat       Date:  2015-12-16       Impact factor: 2.570

9.  Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis.

Authors:  Itziar Montalvo; Alfonso Gutiérrez-Zotes; Marta Creus; Rosa Monseny; Laura Ortega; Joan Franch; Stephen M Lawrie; Rebecca M Reynolds; Elisabet Vilella; Javier Labad
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

Review 10.  Prolactin and psychopathology in schizophrenia: a literature review and reappraisal.

Authors:  Ravi Philip Rajkumar
Journal:  Schizophr Res Treatment       Date:  2014-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.